Ascendant Diagnostics | Tear-Based Breast Cancer Diagnosis
Ascendant Dx is an early stage biotechnology company that was formed in September of 2010 with a focus on developing innovative new approaches to improve the diagnosis of serious disease and conditions.
Ascendant’s first product in development is an in vitro diagnostic assay to detect early stage breast cancer utilizing the proteomic profile present in tears. Implementation of our test in the market place will lead to greater rates of survivability by increasing early detection of breast cancer.
We believe our simple, non-invasive tear-based collection method will rapidly lead to increased participation by individuals who choose not to utilize currently available yearly screening methods.
- Life Sciences
- 535 W. Research Center Blvd.
- Fayetteville, AR 72701
- Omid Moghadam,
- Chief Executive Officer
- Anna Daily, PhD
- Senior Scientist
- Kimberley Fuller,
- Director of Market Research
- and Business Development
Both chambers of the Arkansas Legislature have advanced proposals to move several smaller state agencies into larger ones.
John James, the Acumen Brands founder who now focuses most of his time on launching Hayseed Ventures in Fayetteville, has a vision for the historic Old Post Office building that anchors the Fayetteville downtown square.
Given the massive amounts of data available in today’s world, often, regardless of whether facts or conclusions are correct, they are massively published because of the effortless ability to spread information in a split second.
The 2,300-SF space in the Enterprise Center at the UA tech park will enable Picasolar, an Innovate Arkansas client firm, to reduce the time it takes to produce its patent-pending product.